The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
about
MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cellsEpigenetics in liver disease: from biology to therapeuticsEpigenetic regulation in hepatocellular carcinoma requires long noncoding RNAsAberrant upregulation of 14-3-3σ and EZH2 expression serves as an inferior prognostic biomarker for hepatocellular carcinomaIron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesisThe SNAIL/miR-128 axis regulated growth, invasion, metastasis, and epithelial-to-mesenchymal transition of gastric cancerHigh expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients.EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.Novel therapeutic strategies for targeting liver cancer stem cells.Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behaviorRole of bacterial infection in the epigenetic regulation of Wnt antagonist WIF1 by PRC2 protein EZH2.Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects.Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors.Genetic alteration and misexpression of Polycomb group genes in hepatocellular carcinoma.Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.Effects of EZH2 promoter polymorphisms and methylation status on oral squamous cell carcinoma susceptibility and pathology.The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis.Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma.Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer.Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteinsEpigenetic factors in cancer development: polycomb group proteins.Gene silencing by the Polycomb group proteins and associations with cancer.Roles of the Polycomb group proteins in stem cells and cancer.Biomarkers for predicting future metastasis of human gastrointestinal tumors.Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins.The role of polycomb repressive complexes in biliary tract cancer.In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.New concept: cellular senescence in pathophysiology of cholangiocarcinoma.LncRNA-ANCR down-regulation suppresses invasion and migration of colorectal cancer cells by regulating EZH2 expression.Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.MiR-218-targeting-Bmi-1 mediates the suppressive effect of 1,6,7-trihydroxyxanthone on liver cancer cells.Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.Biliary tract cancer stem cells - translational options and challenges.A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma.Hepatitis B virus X protein regulates the mEZH2 promoter via the E2F1-binding site in AML12 cells.
P2860
Q21245764-A1708CE3-4A52-486B-962E-7C27E631D23DQ27340125-D3A29AC5-25FF-4D90-9B72-FCE54A9965A4Q28079271-D2E92DD6-E968-460A-B65A-B517912FEAD1Q28084553-9101E88B-A3C3-49F2-A7C3-17738E99FB69Q28248070-3C9EAF6B-4E02-45E0-A3A1-1540CCEC8770Q28576835-F09F6F7C-F2C4-4A5F-806C-A49A77090AE7Q33889165-ED295345-5E38-443A-8AD5-6BECC2E26DE5Q34500720-DFFA8BA1-3B56-4F40-AE47-78D2F5617321Q34541488-9048F535-E3B8-4460-AB6F-3D9BEFB9FAC8Q34940971-5C3D5ABC-3F58-4CD8-B260-3EB0C3F2D01AQ34964303-A6492CDB-6D8D-4608-BF3C-D4D7A0A52D4DQ35116342-C4A97141-4A1D-4814-9417-734C775ED3ADQ35696142-468BA7F0-B687-43D6-85BE-4F6CBF72F2E6Q36157946-28A1AF81-6CD4-43E8-B228-1DEEF982115BQ36217858-C2DFE18F-54CA-4A31-AA7D-1FBC052473C0Q36309367-94833917-51E2-4A0D-A7C3-FC3B23CB37E3Q36382605-A6FD0176-B605-422F-8DBB-D99D7BB2CF0BQ36420195-869FC89E-35B2-4BA5-BB71-D9524E31BB42Q37446527-8AF5DD31-6FF2-481E-B301-77913E102157Q37571496-140F0D98-37A5-488B-B119-FA26DB215C77Q37629613-2E6AF5B0-C700-48B4-891C-F9625C758AB1Q37791830-37A36CF0-D9F8-46D1-858B-4F04C8F38535Q37822735-D1EB9345-B459-4288-A5E8-89E1AD9E6304Q37835825-C92F961F-422D-49D2-80A9-9746DED27A0DQ37924588-57509A3F-2100-4C79-BB01-4996EC318E2FQ38078237-4DF29670-2D9F-48EC-8FE9-DB69747E6E86Q38101901-E93C46CB-91BD-485D-AC1B-BFAAE1F3351EQ38271374-370EA76F-D2AB-4402-B13E-96B0B244C140Q38388649-0E21BDE4-C1C6-4B45-83B4-01894748FB59Q38672946-83D0CBF2-7A31-4175-BD56-CB1235C10B3FQ38725914-308223CE-0FAE-418B-8A69-C8CD901C41BDQ38808091-46DF24A0-94A8-489D-8FF9-A2EDADEF70A8Q38857804-8584C916-5D6B-4C06-B176-684C92F6F8EEQ38938564-C086DB77-7E4D-4E8E-A442-E773E8A33FAFQ39191677-7164B04F-6404-4ACB-B22F-ACED4E2B4758Q39192075-B4B68B19-96C1-4286-9723-E6F438CCC541Q39277922-86E1E1E4-9453-4C3E-A2EF-A0F0F5332485Q39279276-9EEA2369-2CEC-494B-93B9-3ADA2B7F702BQ39322941-717343C5-47C7-4019-87A5-E1FB25278D75Q39348204-951F2A84-95F4-4499-8022-E7768D3A2E29
P2860
The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The overexpression of polycomb ...... r of hepatocellular carcinoma.
@en
The overexpression of polycomb ...... r of hepatocellular carcinoma.
@nl
type
label
The overexpression of polycomb ...... r of hepatocellular carcinoma.
@en
The overexpression of polycomb ...... r of hepatocellular carcinoma.
@nl
prefLabel
The overexpression of polycomb ...... r of hepatocellular carcinoma.
@en
The overexpression of polycomb ...... r of hepatocellular carcinoma.
@nl
P2093
P2860
P1476
The overexpression of polycomb ...... r of hepatocellular carcinoma.
@en
P2093
Hiroko Ikeda
Hiroshi Minato
Junpei Yamaguchi
Keita Itatsu
Motoko Sasaki
Seiko Sawada
Tetsuo Ohta
Yasuni Nakanuma
P2860
P2888
P304
P356
10.1038/LABINVEST.2008.52
P577
2008-06-30T00:00:00Z